Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sturgill

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Experimental Cell Research|June 25, 1998
Hypophosphorylation of the RB protein in S and G2 as well as G1 during growth arrestA Yen, R Sturgill
Cancer Research|May 15, 1997
Increasing c-FMS (CSF-1 receptor) expression decreases retinoic acid concentration needed to cause cell differentiation and retinoblastoma protein hypophosphorylationA Yen, R Sturgill, S Varvayanis
Applied Optics|August 25, 2010
Optical hit-miss morphological transformD Casasent, R Schaefer, R Sturgill
Experimental Cell Research|November 25, 1996
FMS (CSF-1 receptor) prolongs cell cycle and promotes retinoic acid-induced hypophosphorylation of retinoblastoma protein, G1 arrest, and cell differentiationA Yen, R Sturgill, S Varvayanis, et al.
NAR Cancer|November 18, 2024
Expanded detection and impact of <i>BAP1</i> alterations in cancerIan R Sturgill, Jesse R Raab, Katherine A Hoadley
Biorxiv : the Preprint Server for Biology|December 4, 2023
Expanded detection and impact of <i>BAP1</i> alterations in cancerIan R Sturgill, Jesse R Raab, Katherine A Hoadley
Experimental Cell Research|August 1, 1997
An RXR-selective analog attenuates the RAR alpha-selective analog-induced differentiation and non-G1-restricted growth arrest of NB4 cellsS C Brooks, R Sturgill, J Choi, et al.
Journal of Neurotrauma|September 1, 2012
Sialidase, chondroitinase ABC, and combination therapy after spinal cord contusion injuryAndrea Mountney, Matthew R Zahner, Elizabeth R Sturgill, et al.
G3 (Bethesda, Md.)|February 19, 2026
Hepatocyte-targeted Bap1 reduction in the liver primes an inflammatory transcriptional responseWilliam C Nenad, Peyton C Kuhlers, Ian R Sturgill, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Experimental Cell Research|June 25, 1998
Hypophosphorylation of the RB protein in S and G2 as well as G1 during growth arrestA Yen, R Sturgill
Cancer Research|May 15, 1997
Increasing c-FMS (CSF-1 receptor) expression decreases retinoic acid concentration needed to cause cell differentiation and retinoblastoma protein hypophosphorylationA Yen, R Sturgill, S Varvayanis
Applied Optics|August 25, 2010
Optical hit-miss morphological transformD Casasent, R Schaefer, R Sturgill
Experimental Cell Research|November 25, 1996
FMS (CSF-1 receptor) prolongs cell cycle and promotes retinoic acid-induced hypophosphorylation of retinoblastoma protein, G1 arrest, and cell differentiationA Yen, R Sturgill, S Varvayanis, et al.
NAR Cancer|November 18, 2024
Expanded detection and impact of <i>BAP1</i> alterations in cancerIan R Sturgill, Jesse R Raab, Katherine A Hoadley
Biorxiv : the Preprint Server for Biology|December 4, 2023
Expanded detection and impact of <i>BAP1</i> alterations in cancerIan R Sturgill, Jesse R Raab, Katherine A Hoadley
Experimental Cell Research|August 1, 1997
An RXR-selective analog attenuates the RAR alpha-selective analog-induced differentiation and non-G1-restricted growth arrest of NB4 cellsS C Brooks, R Sturgill, J Choi, et al.
Journal of Neurotrauma|September 1, 2012
Sialidase, chondroitinase ABC, and combination therapy after spinal cord contusion injuryAndrea Mountney, Matthew R Zahner, Elizabeth R Sturgill, et al.
G3 (Bethesda, Md.)|February 19, 2026
Hepatocyte-targeted Bap1 reduction in the liver primes an inflammatory transcriptional responseWilliam C Nenad, Peyton C Kuhlers, Ian R Sturgill, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Pageof 3